Type 1 diabetes patients who used the new system increased by 2.6 hours/day the amount of time spent in target blood glucose level range.
Oral semaglutide, the first oral GLP-1 receptor agonsist, was approved by the FDA on Sept 20, 2019, becoming the only noninjectable formulation in the class.
US adults with type 2 diabetes have acheived negligible change in blood glucose levels, blood pressure, LDL-C levels, and smoking status in the past 15 years, according to a new study.
Less than half of PCPs responding to a recent survey chose correct values for prediabetes screening tests and seemed unaware of other evidence-based recommendations for prediabetes.
US adults with diagnosed diabetes are no closer to treatment goals than they were in 2005, according to a new study.
Help keep patients with diabetes healthy this flu season with a few of these quick reminders on vaccination, medication, comorbidities, and more.
About 25% of patients with diabetes report asking a physician for a cheaper drug. Skipping doses and pill splitting are tactics used to cut costs.
One US researcher notes that using A1c alone to classify diabetes may misdiagnose >33 million Americans. What are the other options and how well do they work? Read on.
The novel intranasal glucagon delivered with a portable, single-use device could simplify treatment of this dangerous side effect of antidiabetes medications.
ADA 2019 ICYMI: Safety and efficacy of oral semaglutide in patients with T2DM was demonstrated in results of 3 PIONEER program clinical trials. Highlights, here.